胸腺肽α_1对恶性肿瘤化疗患者细胞免疫功能的影响  

Effects of thymosin α_1 on Cellular immune function in patients with malignant tumor during chemotherapy

作　　者：兰海涛[1] 李宏敏[1] 梁良[1] 邓春美[1] 

机构地区：[1]四川省人民医院肿瘤科,四川成都610072

出　　处：《西部医学》2007年第1期15-17,共3页Medical Journal of West China

摘　　要：目的观察胸腺肽1α对恶性肿痛化疗患者细胞免疫功能的影响。方法63例恶性肿瘤患者分为两组,试验细化疗期间同时子胸腺肽α1.6m g/次,皮下注射,每周2次;对照组采用单化疗。两组病例在治疗前后分别检测T淋巴细胞亚群及NK淋巴细胞活性。结果治疗后两组病人的细胞免疫功能不同(Hote lling T2检验,F=2.482,P=0.042),不能认为胸腺肽1α无法提高恶性肿瘤患者的细胞免疫功能;化疗后试验组的CD 3、NK淋巴细胞水平高于对照组,差异接近或小于检验水准(P=0.068,0.034)。结论胸腺肽1α可能改善恶性肿瘤化疗患者的细胞免疫功能。Objective To observe the effects of thymosinα1 on Cellular immune function in patients with malignant tumor during chemotherapy. Methods Sixty-three patients with malignant tumor were divided into two groups receiving chemotherapy or chemotherapy in combination with thymosina, at twice weekly dose of 1.6mg by subcutaneous injection. The peripheral blood T cell subsets （CD3,CD4,CD4/CD8） and natural killer（NK） activity of patients in both groups were measured by flow cytometry before and after treatment. Results After treatment,the cellular immune function were diffierent between chemotherapy＋thymosinal group and control group （Hotelling T^2 test,F= 2. 482. P= 0. 042）. After treatment,the blood levels of CD3 and NK cell activity in chemotherapy＋thymosinal group were higher than that in control group（P=0. 068,0. 034）. Conclusion The Cellular immune function of patients with malignant might be elevated by thymusinal treatment.

关 键 词：胸腺肽Α1 恶性肿痛 化疗 细胞免疫 

分 类 号：R73-361[医药卫生—肿瘤]